Kai Thede, Leverkusen (DE); Anne Mengel, Leverkusen (DE); Clara Christ, Leverkusen (DE); Joachim Kuhnke, Leverkusen (DE); Sarah Anna Liesa Johannes, Leverkusen (DE); Philipp Buchgraber, Leverkusen (DE); Ulrich Klar, Leverkusen (DE); Ulrike Rauh, Leverkusen (DE); Stefan Kaulfuss, Leverkusen (DE); Amaury Ernesto Fernandez-Montalvan, Leverkusen (DE); Nicolas Werbeck, Leverkusen (DE); Ursula Moenning, Leverkusen (DE); Katrin Nowak-Reppel, Leverkusen (DE); Sven Wittrock, Leverkusen (DE); David McKinney, Cambridge, MA (US); Michael H. Serrano-Wu, Cambridge, MA (US); Chris Lemke, Cambridge, MA (US); Mark Fitzgerald, Cambridge, MA (US); Christopher Nasveschuk, Cambridge, MA (US); Kiel Lazarski, Cambridge, MA (US); Steven James Ferrara, Cambridge, MA (US); Laura Furst, Cambridge, MA (US); Guo Wei, Cambridge, MA (US); Patrick Ryan McCarren, Cambridge, MA (US); and Rebecca Ann Harvey, Lancashire (GB)
Assigned to Bayer Aktiengesellschaft, Leverkusen (DE); Bayer Pharma Aktiengesellschaft, Berlin (DE); and The Broad Institute, Inc., Cambridge, MA (US)
Filed by Bayer Aktiengesellschaft, Leverkusen (DE); Bayer Pharma Aktiengesellschaft, Berlin (DE); and The Broad Institute, Inc., Cambridge, MA (US)
Filed on Sep. 8, 2022, as Appl. No. 17/940,617.
Application 17/940,617 is a continuation of application No. 16/764,668, granted, now 11,440,923, previously published as PCT/EP2018/081406, filed on Nov. 15, 2018.
Claims priority of provisional application 62/587,935, filed on Nov. 17, 2017.
Prior Publication US 2023/0112244 A1, Apr. 13, 2023
